Definium Therapeutics(DFTX)
$34.47-0.17 (-0.49%)
DFTX
Definium Therapeutics financials statements
$34.47
At close:-0.17 (-0.49%)
Want to see DFTX full AI Analyst Report?
Definium Therapeutics (DFTX) Ratios
2,488 Followers
Definium Therapeutics Ratios
DFTX's free cash flow for Q3 2026 was $-52.98M. For the 2026 fiscal year, DFTX's free cash flow was increased by $0.00 and operating cash flow was $-52.98M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.29 | 7.25 | 3.22 | 8.16 | 13.18 |
| Quick Ratio | 6.29 | 7.25 | 3.22 | 8.16 | 13.18 |
| Cash Ratio | 3.87 | 7.05 | 3.09 | 7.94 | 12.83 |
| Solvency Ratio | -1.71 | -1.78 | -1.99 | -2.81 | -7.33 |
| Operating Cash Flow Ratio | -1.97 | -2.04 | -2.00 | -2.80 | -4.40 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 311.55M | $ 220.92M | $ 57.47M | $ 126.98M | $ 124.88M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.07 | 0.11 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.09 | 0.18 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.08 | 0.15 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.08 | 0.15 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.32 | 1.25 | 1.59 | 1.13 | 1.08 |
| Debt Service Coverage Ratio | -32.53 | -46.37 | -100.62 | -42.24 | -250.92 |
| Interest Coverage Ratio | -30.34 | -45.52 | -102.03 | -44.37 | -261.43 |
| Debt to Market Cap | 0.00 | 0.04 | 0.10 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.06 | 0.34 | 0.38 | 0.05 | 0.01 |
| Net Debt to EBITDA | 1.45 | 2.38 | 0.92 | 2.65 | 1.46 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 98.77% |
| EBT Per EBIT | 110.51% | 104.58% | 101.99% | 85.63% | 100.36% |
| Return on Assets (ROA) | -41.76% | -35.97% | -76.87% | -27.80% | -56.73% |
| Return on Equity (ROE) | -55.30% | -45.01% | -122.52% | -31.32% | -61.34% |
| Return on Capital Employed (ROCE) | -44.54% | -39.47% | -101.70% | -43.61% | -62.74% |
| Return on Invested Capital (ROIC) | -44.54% | -39.47% | -101.70% | -36.27% | -61.97% |
| Return on Tangible Assets | -43.74% | -38.51% | -91.97% | -32.29% | -67.80% |
| Earnings Yield | -15.37% | -22.16% | -66.80% | -69.62% | -16.42% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.26 | 0.76 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1392.13 | -477.43 | -239.07 | -582.94 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 1392.13 | 477.43 | 239.07 | 582.94 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.47 | -1.12 | -1.64 | -1.62 | -1.67 |
| Free Cash Flow Per Share | -1.47 | -1.12 | -1.64 | -1.62 | -1.67 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | -3.62 | -4.56 | -696.38 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -11.00% | -16.14% | -44.91% | -73.86% | -8.09% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.50 | -4.51 | -1.50 | -1.20 | -6.09 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.60 | 2.03 | 1.83 | 0.45 | 3.74 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.09 | -6.20 | -2.23 | -1.35 | -12.37 |
| Price-to-Operating Cash Flow Ratio | -9.09 | -6.20 | -2.23 | -1.35 | -12.37 |
| Price-to-Earnings Growth (PEG) Ratio | -0.19 | 0.12 | -0.03 | 0.02 | -0.08 |
| Enterprise Value Multiple | -5.26 | -2.25 | -0.62 | 1.17 | -4.75 |
| Enterprise Value | 938.26M | 238.52M | 57.74M | -74.18M | 433.17M |
| EV to EBITDA | -5.26 | -2.25 | -0.62 | 1.38 | -4.75 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -7.13 | -3.01 | -0.90 | 1.48 | -9.45 |
| EV to Operating Cash Flow | -7.13 | -3.01 | -0.90 | 1.48 | -9.45 |
| Tangible Book Value Per Share | 3.50 | 3.14 | 1.47 | 4.13 | 4.56 |
| Shareholders’ Equity Per Share | 3.72 | 3.43 | 2.00 | 4.89 | 5.54 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.06 | -1.54 | -2.44 | -1.84 | -3.40 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.83 | 0.99 |
| Interest Burden | 1.03 | 1.02 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.72 | 0.73 | 0.67 | 0.88 | 0.49 |
Currency in USD
